Seattle Children’s launches BrainChild Bio to accelerate CAR T-cell therapies for children with brain tumors
January 4, 2024
Seattle Children's launched BrainChild Bio, Inc. to accelerate the advancement of chimeric antigen receptor (CAR) T-cell therapies in central nervous system (CNS) tumors.... Read More >>